Elise Konradsson

Dr. Elise Konradsson

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2019 in British Journal of Radiology
Verified
Journal Article
Closed access
GAGabriel Adrian
Gabriel Adrian
EKElise Konradsson
Elise Konradsson
MLMichael Lempart
Michael Lempart
SBSven Bäck
Sven Bäck
CCCrister Ceberg
Crister Ceberg
KPKristoffer Petersson
Kristoffer Petersson
Objective: Recent in vivo results have shown prominent tissue sparing effect of radiotherapy with ultra-high dose rates (FLASH) compared to conventional dose rates (CONV). Oxygen depletion has been proposed as the underlying mechanism, but in vitro data to support this have been lacking. The aim of the current study was to compare FLASH to CONV irradiation under different oxygen concentrations in vitro. Methods: Prostate cancer cells were irradiated at different oxygen concentrations (relative partial pressure ranging between 1.6 and 20%) with a 10 MeV electron beam at a dose rate of either 600 Gy/s (FLASH) or 14 Gy/min (CONV), using a modified clinical linear accelerator. We evaluated the surviving fraction of cells using clonogenic assays after irradiation with doses ranging from 0 to 25 Gy. Results: Under normoxic conditions, no differences between FLASH and CONV irradiation were found. For hypoxic cells (1.6%), the radiation response was similar up to a dose of about 5–10 Gy, above which increased survival was shown for FLASH compared to CONV irradiation. The increased survival was shown to be significant at 18 Gy, and the effect was shown to depend on oxygen concentration. Conclusion: The in vitro FLASH effect depends on oxygen concentration. Further studies to characterize and optimize the use of FLASH in order to widen the therapeutic window are indicated. Advances in knowledge: This paper shows in vitro evidence for the role of oxygen concentration underlying the difference between FLASH and CONV irradiation.

13 May 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
EKElise Konradsson
Elise Konradsson
MAMaja L. Arendt
Maja L. Arendt
KJKristine Bastholm Jensen
Kristine Bastholm Jensen
BBBetina Børresen
Betina Børresen
AHAnders E. Hansen
Anders E. Hansen
KPKristoffer Petersson
Kristoffer Petersson
FLASH radiotherapy has emerged as a treatment technique with great potential to increase the differential effect between normal tissue toxicity and tumor response compared to conventional radiotherapy. To evaluate the feasibility of FLASH radiotherapy in a relevant clinical setting, we have commenced a feasibility and safety study of FLASH radiotherapy in canine cancer patients with spontaneous superficial solid tumors or microscopic residual disease, using the electron beam of our modified clinical linear accelerator. The setup for FLASH radiotherapy was established using a short electron applicator with a nominal source-to-surface distance of 70 cm and custom-made Cerrobend blocks for collimation. The beam was characterized by measuring dose profiles and depth dose curves for various field sizes. Ten canine cancer patients were included in this initial study; seven patients with nine solid superficial tumors and three patients with microscopic disease. The administered dose ranged from 15 to 35 Gy. To ensure correct delivery of the prescribed dose, film measurements were performed prior to and during treatment, and a Farmer-type ion-chamber was used for monitoring. Treatments were found to be feasible, with partial response, complete response or stable disease recorded in 11/13 irradiated tumors. Adverse events observed at follow-up ranging from 3-6 months were mild and consisted of local alopecia, leukotricia, dry desquamation, mild erythema or swelling. One patient receiving a 35 Gy dose to the nasal planum, had a grade 3 skin adverse event. Dosimetric procedures, safety and an efficient clincal workflow for FLASH radiotherapy was established. The experience from this initial study will be used as a basis for a veterinary phase I/II clinical trial with more specific patient inclusion selection, and subsequently for human trials.

22 June 2020 in Radiation Research
Verified
Journal Article
Open access
PDF file
EKElise Konradsson
Elise Konradsson
CCCrister Ceberg
Crister Ceberg
MLMichael Lempart
Michael Lempart
BBBörje Blad
Börje Blad
SBSven Bäck
Sven Bäck
KPKristoffer Petersson
Kristoffer Petersson
In the novel and promising radiotherapy technique known as FLASH, ultra-high dose-rate electron beams are used. As a step towards clinical trials, dosimetric advances will be required for accurate dose delivery of FLASH. The purpose of this study was to determine whether a built-in transmission chamber of a clinical linear accelerator can be used as a real-time dosimeter to monitor the delivery of ultra-high-dose-rate electron beams. This was done by modeling the drop-in ion-collection efficiency of the chamber with increasing dose-per-pulse values, so that the ion recombination effect could be considered. The raw transmission chamber signal was extracted from the linear accelerator and its response was measured using radiochromic film at different dose rates/dose-per-pulse values, at a source-to-surface distance of 100 cm. An increase of the polarizing voltage, applied over the transmission chamber, by a factor of 2 and 3, improved the ion-collection efficiency, with corresponding increased efficiency at the highest dose-per-pulse values by a factor 1.4 and 2.2, respectively. The drop-in ion-collection efficiency with increasing dose-per-pulse was accurately modeled using a logistic function fitted to the transmission chamber data. The performance of the model was compared to that of the general theoretical Boag models of ion recombination in ionization chambers. The logistic model was subsequently used to correct for ion recombination at dose rates ranging from conventional to ultra-high, making the transmission chamber useful as a real-time monitor for the dose delivery of FLASH electron beams in a clinical setup.

11 September 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
BBBetina Børresen
Betina Børresen
MAMaja Louise Arendt
Maja Louise Arendt
EKElise Konradsson
Elise Konradsson
KJKristine Bastholm Jensen
Kristine Bastholm Jensen
SBSven Åj. Bäck
Sven Åj. Bäck
KPKristoffer Petersson
Kristoffer Petersson
Background: FLASH radiotherapy (RT) is a novel method for delivering ionizing radiation, which has been shown in preclinical studies to have a normal tissue sparing effect and to maintain anticancer efficacy as compared to conventional RT. Treatment of head and neck tumors with conventional RT is commonly associated with severe toxicity, hence the normal tissue sparing effect of FLASH RT potentially makes it especially advantageous for treating oral tumors. In this work, the objective was to study the adverse effects of dogs with spontaneous oral tumors treated with FLASH RT.Methods: Privately-owned dogs with macroscopic malignant tumors of the oral cavity were treated with a single fraction of ≥30Gy electron FLASH RT and subsequently followed for 12 months. A modified conventional linear accelerator was used to deliver the FLASH RT.Results: Eleven dogs were enrolled in this prospective study. High grade adverse effects were common, especially if bone was included in the treatment field. Four out of six dogs, who had bone in their treatment field and lived at least 5 months after RT, developed osteoradionecrosis at 3-12 months post treatment. The treatment was overall effective with 8/11 complete clinical responses and 3/11 partial responses.Conclusion: This study shows that single-fraction high dose FLASH RT was generally effective in this mixed group of malignant oral tumors, but the risk of osteoradionecrosis is a serious clinical concern. It is possible that the risk of osteonecrosis can be mitigated through fractionation and improved dose conformity, which needs to be addressed before moving forward with clinical trials in human cancer patients.

2 July 2022 in Advances in Radiation Oncology
Verified
Journal Article
Open access
EKElise Konradsson
Elise Konradsson
ELEmma Liljedahl
Emma Liljedahl
EGEmma Gustafsson
Emma Gustafsson
GAGabriel Adrian
Gabriel Adrian
SBSarah Beyer
Sarah Beyer
HRHenrietta Nittby Redebrandt
Henrietta Nittby Redebrandt
To ensure a clinical translation of FLASH radiation therapy (FLASH-RT) for a specific tumor type, studies on tumor control and toxicity within the same biological system are needed. In this study, our objective was to evaluate tumor control and toxicity for hypofractionated FLASH-RT and conventional radiation therapy (CONV-RT) in an immunocompetent rat glioma model. Fisher 344 rats (N = 68) were inoculated subcutaneously with NS1 glioma cells and randomized into groups (n = 9-10 per group). CONV-RT (∼8 Gy/min) or FLASH-RT (70-90 Gy/s) was administered in 3 fractions of either 8 Gy, 12.5 Gy, or 15 Gy using a 10-MeV electron beam. The maximum tumor diameter was measured weekly, and overall survival was determined until day 100. Long-term tumor control was defined as no evident tumor on day 100. Animals were evaluated for acute dermal side effects at 2 to 5 weeks after completed RT and for late dermal side effects at 3 months after initiation of treatment. Survival was significantly increased in all irradiated groups compared with control animals (P < .001). In general, irradiated tumors started to shrink at 1 week post–completed RT. In 40% (23 of 58) of the irradiated animals, long-term tumor control was achieved. Radiation-induced skin toxic effects were mild and consisted of hair loss, erythema, and dry desquamation. No severe toxic effect was observed. There was no significant difference between FLASH-RT and CONV-RT in overall survival, acute side effects, or late side effects for any of the dose levels. This study shows that hypofractionated FLASH-RT results in long-term tumor control rates similar to those of CONV-RT for the treatment of large subcutaneous glioblastomas in immunocompetent rats. Neither treatment technique induced severe skin toxic effects. Consequently, no significant difference in toxicity could be resolved, suggesting that higher doses may be required to detect a FLASH sparing of skin.

11 September 2023 in Medical Physics
Verified
Journal Article
Open access
EKElise Konradsson
Elise Konradsson
RSRebecka Ericsson Szecsenyi
Rebecka Ericsson Szecsenyi
GAGabriel Adrian
Gabriel Adrian
MCMizgin Coskun
Mizgin Coskun
BBBetina Børresen
Betina Børresen
CCCrister Ceberg
Crister Ceberg
Purpose: The increased normal tissue tolerance for FLASH radiotherapy (FLASH‐RT), as compared to conventional radiotherapy, was first observed in ultra‐high dose rate electron beams. Initial clinical trials in companion animals have revealed a high risk of developing osteoradionecrosis following high‐dose single‐fraction electron FLASH‐RT, which may be related to inhomogeneities in the dose distribution. In the current study, we aim to evaluate the possibilities of intensity‐modulated electron FLASH‐RT in a clinical setting to ensure a homogeneous dose distribution in future veterinary and human clinical trials.Methods: Our beam model in the treatment planning system electronRT (.decimal, LLC, Sanford, FL, USA) was based on a 10‐MeV electron beam from a clinical linear accelerator used to treat veterinary patients with FLASH‐RT in a clinical setting. In electronRT, the beam can be intensity‐modulated using tungsten island blocks in the electron block cutout, and range‐modulated using a customized bolus with variable thickness. Modulations were first validated in a heterogeneous phantom by comparing measured and calculated dose distributions. To evaluate the impact of intensity modulation in superficial single‐fraction FLASH‐RT, a treatment planning study was conducted, including eight canine cancer patient cases with simulated tumors in the head‐and‐neck region. For each case, treatment plans with and without intensity modulation were created for a uniform bolus and a range‐modulating bolus. Treatment plans were evaluated using a target dose homogeneity index (HI), a conformity index (CI), the near‐maximum dose outside the target (), and the near‐minimum dose to the target ().Results: By adding intensity modulation to plans with a uniform bolus, the HI could be improved (p = 0.017). The combination of a range‐modulating bolus and intensity modulation provided a further significant improvement of the HI as compared to using intensity modulation in combination with a uniform bolus (p = 0.036). The range‐modulating bolus also improved the CI compared to using a uniform bolus, both with an open beam (p = 0.046) and with intensity modulation (p = 0.018), as well as increased the (p = 0.036 with open beam and p = 0.05 with intensity modulation) and reduced the median (not significant).Conclusions: By using intensity‐modulated electron FLASH‐RT in combination with range‐modulating bolus, the target dose homogeneity and conformity in canine patients with simulated tumors in complex areas in the head‐and‐neck region could be improved. By utilizing this technique, we hope to decrease the dose outside the target volume and avoid hot spots in future clinical electron FLASH‐RT studies, thereby reducing the risk of radiation‐induced toxicity.